PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER

前列腺癌、肺癌、结直肠癌和卵巢癌 (PLCO)

• 批准号: 6369512
• 负责人: Timothy Robert Church
• 金额: --
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-09-30 至 2011-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6369512
• 关键词: biopsy; blood chemistry; cancer prevention; clinical trials; colorectal neoplasms; diagnosis quality /standard; diagnostic tests; digital imaging; early diagnosis; endoscopy; female; gender difference; human mortality; human old age (65+); human subject; lung neoplasms; male; mass screening; neoplasm /cancer diagnosis; ovary neoplasms; prognosis; prostate neoplasms; prostate specific antigen; thoracic radiography; ultrasonography

The Prostate, Lung, Colon-rectum and Ovary Cancer Screening Trial is designed to determine in screenees aged 60-74 years at entry whether: a. In females and males (1) screening with flexible sigmoidoscopy (60 cm sigmoidoscope) can reduce mortality from colo-rectal cancer; and, (2) screening with chest x-ray can reduce mortality from lung cancer. b.In males (1) screening with digital rectal examination plus serum prostate-specific antigen (PSA) can reduce mortality from prostate cancer; c. In females (1) screening with pelvic examination plus CA 125 and transvaginal ultrasound can reduce mortality from ovarian cancer; The secondary objectives are: (1) to assess screening variables other than mortality for each of the interventions including sensitivity, specificity, and positive predictive value; (2) to assess incidence, stage, and survival experience of cancer cases and (3) to investigate the mortality predictive value of biologic and or prognostic characterizations of tumor tissue as intermediate endpoints. This contractor will recruit and randomize to screening or control 20,000 subjects in equal gender balance. Screening will be annual for four years, except that sigmoidoscopy will be done only in the initial and last screen. Subjects will be followed for ten years from entry. A total of 148,000 subjects will be recruited by ten participating Screening Centers. The trial also includes a Data Management and Coordinating Center and a Laboratory for blood assays.

前列腺，肺癌，结肠-直肠和卵巢癌筛查试验是

项目成果

Pancreatic cancer risk: associations with meat-derived carcinogen intake in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort.

• DOI: 10.1002/mc.20794
• 发表时间: 2012-01
• 期刊: MOLECULAR CARCINOGENESIS
• 影响因子: 4.6
• 作者: Anderson, Kristin E.;Mongin, Steven J.;Sinha, Rashmi;Stolzenberg-Solomon, Rachael;Gross, Myron D.;Ziegler, Regina G.;Mabie, Jerome E.;Risch, Adam;Kazin, Sally S.;Church, Timothy R.
• 通讯作者: Church, Timothy R.

False-positive cancer screens and health-related quality of life.

假阳性癌症筛查和健康相关的生活质量。

• DOI: 10.1097/00002820-200409000-00003
• 发表时间: 2004
• 期刊: Cancer nursing
• 影响因子: 2.6
• 作者: McGovern,PatriciaM;Gross,CynthiaR;Krueger,RichardA;Engelhard,DeborahA;Cordes,JillE;Church,TimothyR
• 通讯作者: Church,TimothyR

A mathematical model of case-ascertainment bias: Applied to case-control studies nested within a randomized screening trial.

病例确定偏倚的数学模型：应用于随机筛选试验中的病例对照研究。

• DOI: 10.1371/journal.pone.0194608
• 发表时间: 2018
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Jansen,RickJ;Alexander,BruceH;Hayes,RichardB;Miller,AnthonyB;Wacholder,Sholom;Church,TimothyR
• 通讯作者: Church,TimothyR